Psilocybin as a Novel Therapy for Residual Anhedonia

The primary objective is to evaluate whether a single dose of psilocybin (25 mg), compared to placebo, can restore fronto-striatal reward circuit function and thereby improve anhedonia and emotional blunting in individuals with residual symptoms despite ongoing SSRI or SNRI treatment. This will be assessed using precision functional mapping (PFM), task-based fMRI, and clinical rating scales (DARS).

NCT Number	NCT07607938
Lead Sponsor	NYU Langone Health Collaborators: National Institute of Mental Health (NIMH)
Conditions	Anhedonia, Emotional Blunting
Enrollment	90 participants
Start Date	2026-07
Primary Completion	2030-08-01 (estimated)
Study Completion	2030-09-30 (estimated)
Updated on ClinicalTrials.gov	2026-05-27